1.75%
-4.53%
-20.92%
-20.92%
6.90%
-59.04%
-88.38%
AI Spotlight on DNTH
Company Description
Dianthus Therapeutics, Inc.operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases.It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Dianthus Therapeutics, Inc.was incorporated in 2015 and is based in New York, New York.
Market Data
| Last Price | 22.15 |
| Change Percentage | 1.75% |
| Open | 21.42 |
| Previous Close | 21.77 |
| Market Cap ( Millions) | 656 |
| Volume | 269539 |
| Year High | 33.77 |
| Year Low | 18.35 |
| M A 50 | 23.12 |
| M A 200 | 25.59 |
Financial Ratios
| FCF Yield | -7.60% |
| Dividend Yield | 0.00% |
| ROE | -21.68% |
| Debt / Equity | 0.09% |
| Net Debt / EBIDTA | 41.60% |
| Price To Book | 2.24 |
| Price Earnings Ratio | -11.3 |
| Price To FCF | -13.16 |
| Price To sales | 122.17 |
| EV / EBITDA | -7.76 |
News
- Jan -30 - Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences
- Jan -08 - Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
- Nov -07 - Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates
- Nov -07 - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
- Nov -04 - Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
- Oct -15 - Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
- Oct -09 - Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength?
- Aug -08 - Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates
- Aug -08 - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
- Jul -08 - Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
- Jun -28 - Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
- Jun -12 - Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
- May -30 - Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
- May -20 - Research Analysts Offer Predictions for Dianthus Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:DNTH)
- May -09 - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
- May -08 - Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
- May -03 - Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apr -11 - Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
- Apr -05 - Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mar -26 - Strong Q1 a Boon for the Rest of 2024? 5 Top Growth Picks
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Novel Medicines
Expected Growth : 9.27 %
What the company do ?
Novel Medicines from Dianthus Therapeutics, Inc. are innovative, targeted therapies for rare genetic disorders, leveraging proprietary technology to address unmet medical needs.
Why we expect these perspectives ?
Dianthus Therapeutics' novel medicines drive 9.27% growth, fueled by increasing demand for innovative treatments, strategic partnerships, and expanding pipeline of gene therapies. Strong R&D investments, favorable regulatory environments, and growing awareness of rare genetic disorders also contribute to this growth.
Dianthus Therapeutics, Inc. Products
| Product Range | What is it ? |
|---|---|
| DTH-101 | DTH-101 is a novel, oral, small molecule inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) for the treatment of autoimmune diseases. |
| DTH-102 | DTH-102 is a proprietary, oral, small molecule inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO) for the treatment of cancer. |
| DTH-103 | DTH-103 is a novel, oral, small molecule inhibitor of the enzyme Bruton's tyrosine kinase (BTK) for the treatment of B-cell malignancies. |
Dianthus Therapeutics, Inc.'s Porter Forces
Threat Of Substitutes
Dianthus Therapeutics, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.
Bargaining Power Of Customers
Dianthus Therapeutics, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized, making it difficult for customers to switch to alternative suppliers.
Bargaining Power Of Suppliers
Dianthus Therapeutics, Inc. relies on a few key suppliers for raw materials and equipment. While the company has some bargaining power due to its size, the suppliers also have some leverage due to the specialized nature of the products.
Threat Of New Entrants
The biotechnology industry is highly competitive, and new entrants can easily disrupt the market with innovative products and services. Dianthus Therapeutics, Inc. needs to continuously innovate and improve its products to stay ahead of the competition.
Intensity Of Rivalry
The biotechnology industry is highly competitive, with many established players and new entrants vying for market share. Dianthus Therapeutics, Inc. faces intense competition from companies with similar products and services.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 0.35% |
| Debt Cost | 3.95% |
| Equity Weight | 99.65% |
| Equity Cost | 3.95% |
| WACC | 3.95% |
| Leverage | 0.35% |
Dianthus Therapeutics, Inc. : Quality Control
Dianthus Therapeutics, Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CSBR | Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach … |
| TCRX | TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment … |
| KYMR | Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It … |
| ONCT | Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal … |
| TARS | Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Dianthus Therapeutics
A-Score
1-Year Total Return ->
🥈
Kymera Therapeutics
A-Score
1-Year Total Return ->
🥉
Tarsus Pharmaceuticals
A-Score
1-Year Total Return ->
4
Champions Oncology
A-Score
1-Year Total Return ->
5
Oncternal Therapeutics
A-Score
1-Year Total Return ->
6
